Skye Bioscience Reports 22.3% Weight Loss at 52 Weeks with Nimacimab Combination Therapy
Summary
Skye Bioscience reported strong 52-week interim data for its nimacimab and semaglutide combination therapy, showing 22.3% weight loss and reduced weight regain, positioning it competitively in the obesity market.
Key Events
-
Significant Weight Loss Achieved
Nimacimab combined with semaglutide achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, demonstrating competitive efficacy.
-
Enhanced Durability in Weight Management
The combination therapy reduced weight regain by over 50% during a 13-week off-therapy follow-up compared to semaglutide alone (17.8% vs. 37.3%), indicating improved long-term efficacy.
-
Favorable Safety and Tolerability Profile
The combination treatment maintained a strong safety and tolerability profile over 52 weeks, with no serious adverse events or adverse events of special interest reported.
-
Advancing to Higher-Dose Phase 2b Study
The company plans to advance nimacimab into a Phase 2b study to evaluate higher doses and optimize the regimen, with full topline data from the Phase 2a extension expected in Q3 2026.
Analysis
Skye Bioscience announced highly positive interim 52-week results from its Phase 2a extension study of nimacimab in combination with semaglutide for obesity. The combination achieved a mean weight loss of 22.3% at 52 weeks, with no plateau observed, positioning it competitively against other leading obesity treatments. Crucially, the data also showed a significant reduction in weight regain during off-therapy follow-up, demonstrating enhanced durability compared to semaglutide alone. The therapy maintained a strong safety and tolerability profile. While the company's cash runway extends into Q4 2026, excluding the costs for a planned Phase 2b study, these robust clinical results significantly de-risk future financing efforts and support the advancement of nimacimab into higher-dose studies.
At the time of this filing, SKYE was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.4M. The 52-week trading range was $0.68 to $5.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.